Nektar Therapeutics preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study
שיחת ועידה Nektar Therapeutics
Nektar Therapeutics Conference call will be held on 26/09/2019. During the earnings conference call's session Nektar Therapeutics will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Nektar Therapeutics for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, and immunology. Our research and development activities involve small molecule drugs, peptides and protein biologic drug candidates. We create innovative drug candidates by using our proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of pharmacophores to create new molecular entities. Polymer chemistry is a science focused on the synthesis or bonding of polymer architectures with drug molecules to alter the properties of a molecule.קרא עוד שיחת ועידה